Raphael Pharmaceutical Inc. is a pioneering drug research and development company dedicated to discovering and advancing life-enhancing therapies based on cannabinoids. By collaborating with leading scientific experts and leveraging cutting-edge technologies, Raphael is committed to developing safe and effective cannabinoid-based treatments for a range of challenging medical conditions.
Raphael Pharmaceutical has established strategic partnerships with Rambam MedTech and The Shanti Medical Cannabis Research Center at Rambam Health Care Campus. These collaborations focus on investigating and deciphering the mechanisms which enable cannabinoids to be effective in the treatment of patients with various diseases, including:
Over the past five years, Raphael Pharmaceutical has invested approximately $3.5 million into these groundbreaking studies. This investment has resulted in signigicatn progress, including:
-
Authorization of a clinical trial for COVID-19 patients.
-
A clinical proof-of-concept trial in the US evaluating Raphael's proprietary formula for RA patients, which recently concluded with highly encouraging results.
-
Successful identification of a specific cannabis strain belonging to Raphael, which demonstrated the ability to attenuate chronic lung inflammation and asthma in both mouse models and human-derived immune cells.
Looking ahead, Raphael Pharmaceutical will continue these vital collaborations to explore cannabinoid-based formulas for diseases that currently lack effective solutions. By driving innovation and leveraging its partnerships, Raphael is committed to delivering transformative therapies to patients worldwide.